3D Printing and Advanced Robotics

3D PARS brings together 3D printing and advanced robotics to create new biomedical products, services and applications for the benefit of all. 3D PARS directs the advancement of these new technologies in a comprehensive environment by providing consultation, development, service, testing, evaluation, training and education for a global market. From the idea to the bench, the prototype to the clinical trial, and the satellite lab to the classroom, 3D PARS is there! Dr. Mauris DeSilva created 3D PARS as a lean, flexible, and geographically responsive startup company with expertise in delivering biotech and research products and services to a wide array of customers in a variety of settings. By bringing scientists, technologists, engineers, policy makers, resource managers and educators together, Dr. DeSilva envisions 3D PARS as a facilitator for creative, innovative translational research in biotechnology, 3D printing and robotics. 3D PARS is also developing novel training and education programs geared to inform professionals and engage K-20 students and teachers.

Celexion LLC

Celexion is a protein discovery and engineering company based in Cambridge, Massachusetts. We use our proprietary SECANTâ„¢ platform to display complex proteins on the surface of eukaryotic cells. This platform, combined with state-of-the-art library construction and screening capabilities, allows us to rapidly discover and engineer new proteins for applications in therapeutics, diagnostics, and life science tools.

Avacta Analytical

Avacta Analytical provided analytical contract research and innovative instrumentation to the biopharmaceutical sector before the sale of its business in 2015.

Antoon Santegoeds

Website of the past company as the current company has no business website.

BRT Blood Reprogramming Technologies Lda

Blood Reprogramming Technologies (BRT) was founded in March 2017 as a spin-off from the Center for Neuroscience and Cell Biology, University of Coimbra in Portugal. BRT is specialized in R&D and in the use of direct cell reprogramming technologies to generate autologous blood products with clinical application for regenerative medicine. We are developing blood products focusing on hematopoietic stem cell (HSC) transplantation. We aim to serve patients by translating scientific discoveries into products for blood regeneration. Our mission is to improve patients’ health by increasing the therapeutic efficacy of currently performed treatments for blood-based diseases. At the same time we aim to reduce the incidence of adverse side effects that represent a huge economic burden for healthcare systems.